Product Information
HYDROXYZINE HCL 25 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0326 per EA under NDC 16571011450. Its NADAC has been published 139 times since Feb 7, 2024.
FDA first approved this application on Aug 17, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571011450
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROXYZINE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA217652FDA Approved
8/17/2023
TE Code
AB
On Market Since
8/22/2023
Pharmacological Classes
Price Statistics
The NADAC for HYDROXYZINE HCL 25 MG TABLET has been published 139 times since Feb 7, 2024, and over the history we have for it it has declined 25.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0326 per EA |
|---|---|
| All-time high | $0.0478 (Apr 10, 2024) |
| All-time low | $0.0326 (Sep 23, 2026) |
| 52-week high | $0.0368 |
| 52-week low | $0.0326 |
| Median price | $0.0370 |
| Average price | $0.0387 |
| Largest weekly change | -27.4% (Nov 20, 2024) |
| Weeks tracked | 139 |
| Tracking since | Feb 7, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
hydroxyzine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antihistamine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROXYZINE HCL 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HYDROXYZINE HCL 25 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0326 per EA (NDC 16571011450), effective Sep 30, 2026.
How has the price of HYDROXYZINE HCL 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for HYDROXYZINE HCL 25 MG TABLET has declined 25.2%. It has been tracked across 139 weekly CMS publications since Feb 7, 2024.
What are the highest and lowest recorded NADAC prices for HYDROXYZINE HCL 25 MG TABLET?
Since Feb 7, 2024, the NADAC for HYDROXYZINE HCL 25 MG TABLET has ranged from a low of $0.0326 (Sep 23, 2026) to a high of $0.0478 (Apr 10, 2024), with a median of $0.0370 per EA.
Are there cheaper alternatives to HYDROXYZINE HCL 25 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as HYDROXYZINE HCL 25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures HYDROXYZINE HCL 25 MG TABLET?
HYDROXYZINE HCL 25 MG TABLET (NDC 16571011450) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.